Abstract
The scope of this textbook is to provide an overview of the latest translational research in the field of lupus pathogenesis, with particular emphasis on how these discoveries progress in parallel with therapeutic drug development. Systemic lupus erythematosus (SLE) is a multifaceted disease with a number of well-defined immune pathways that are dysregulated, resulting in an immune-mediated chronic inflammatory injury at target organs. As knowledge of these pathways evolves to provide opportunities for targeted drug therapy and lays the foundation for personalized medicine, clinicians and researchers need to keep up with the ever-expanding medical and scientific literature.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R et al (2016) Systemic lupus erythematosus. Nat Rev Dis Primers 2:16039
Liu Y, Kaplan MJ (2018) Cardiovascular disease in systemic lupus erythematosus: an update. Curr Opin Rheumatol 30(5):441–448
Davidson A (2016) What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol 12(3):143–153
Song K, Liu L, Zhang X, Chen X (2020) An update on genetic susceptibility in lupus nephritis. Clin Immunol 210:108272. https://doi.org/10.1016/j.clim.2019.108272
Chung SA, Brown EE, Williams AH, Ramos PS, Berthier CC, Bhangale T et al (2014) Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. J Am Soc Nephrol 25(12):2859–2870
Niu Z, Zhang P, Tong Y (2015) Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. Int J Rheum Dis 18(1):17–28
Xu R, Li Q, Liu R, Shen J, Li M, Zhao M et al (2017) Association analysis of the MHC in lupus nephritis. J Am Soc Nephrol 28(11):3383–3394
Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF et al (1996) Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 97(5):1348–1354
Tsang ASMW, Nagelkerke SQ, Bultink IE, Geissler J, Tanck MW, Tacke CE et al (2016) Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. Rheumatology (Oxford) 55(5):939–948
Sanchez E, Nadig A, Richardson BC, Freedman BI, Kaufman KM, Kelly JA et al (2011) Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis 70(10):1752–1757
Khan SQ, Khan I, Gupta V (2018) CD11b activity modulates pathogenesis of lupus nephritis. Front Med (Lausanne). 5:52
Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, et al (2008) Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet 4(5):e1000084. https://doi.org/10.1371/journal.pgen.1000084
Bolin K, Sandling JK, Zickert A, Jonsen A, Sjowall C, Svenungsson E, et al (2013) Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis. PLoS One 8(12):e84450. https://doi.org/10.1371/journal.pone.0084450
Conti F, Spinelli FR, Alessandri C, Valesini G (2011) Toll-like receptors and lupus nephritis. Clin Rev Allergy Immunol 40(3):192–198
Soliman S, Mohan C (2017) Lupus nephritis biomarkers. Clin Immunol 185:10–20
Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ et al (2019) The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol 20(7):902–914
Der E, Suryawanshi H, Morozov P, Kustagi M, Goilav B, Ranabothu S et al (2019) Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol 20(7):915–927
Hanly JG (2014) Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 10(6):338–347
Schwartz N, Stock AD, Putterman C (2019) Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol 15(3):137–152
Cohen D, Rijnink EC, Nabuurs RJ, Steup-Beekman GM, Versluis MJ, Emmer BJ et al (2017) Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. Rheumatology (Oxford) 56(1):77–86
Hirohata S, Miyamoto T (1990) Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 33(5):644–649
Trysberg E, Carlsten H, Tarkowski A (2000) Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 9(7):498–503
Okamoto H, Katsumata Y, Nishimura K, Kamatani N (2004) Interferon-inducible protein 10/CXCL10 is increased in the cerebrospinal fluid of patients with central nervous system lupus. Arthritis Rheum 50(11):3731–3732
Iikuni N, Okamoto H, Yoshio T, Sato E, Kamitsuji S, Iwamoto T et al (2006) Raised monocyte chemotactic protein-1 (MCP-1)/CCL2 in cerebrospinal fluid of patients with neuropsychiatric lupus. Ann Rheum Dis 65(2):253–256
Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narvaez A, Davila-Maldonado L, Atisha-Fregoso Y, Llorente L et al (2007) Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 56(4):1242–1250
Fragoso-Loyo H, Atisha-Fregoso Y, Llorente L, Sanchez-Guerrero J (2013) Inflammatory profile in cerebrospinal fluid of patients with headache as a manifestation of neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford) 52(12):2218–2222
Yoshio T, Okamoto H, Kurasawa K, Dei Y, Hirohata S, Minota S (2016) IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus. Lupus 25(9):997–1003
Raison CL, Demetrashvili M, Capuron L, Miller AH (2005) Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19(2):105–123
Winfield JB, Shaw M, Silverman LM, Eisenberg RA, Wilson HA 3rd, Koffler D (1983) Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am J Med 74(5):837–844
Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T (1992) Interferon-alpha in lupus psychosis. Arthritis Rheum 35(4):417–422
Fragoso-Loyo H, Atisha-Fregoso Y, Nunez-Alvarez CA, Llorente L, Sanchez-Guerrero J (2012) Utility of interferon-alpha as a biomarker in central neuropsychiatric involvement in systemic lupus erythematosus. J Rheumatol 39(3):504–509
Santer DM, Yoshio T, Minota S, Moller T, Elkon KB (2009) Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol 182(2):1192–1201
Trysberg E, Nylen K, Rosengren LE, Tarkowski A (2003) Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 48(10):2881–2887
DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B (2001) A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 7(11):1189–1193
Matus S, Burgos PV, Bravo-Zehnder M, Kraft R, Porras OH, Farias P et al (2007) Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J Exp Med 204(13):3221–3234
Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Clarke A et al (2011) Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 70(10):1726–1732
Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N et al (1987) Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 317(5):265–271
Yoshio T, Hirata D, Onda K, Nara H, Minota S (2005) Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol 32(1):34–39
Bialas AR, Presumey J, Das A, van der Poel CE, Lapchak PH, Mesin L et al (2017) Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature 546(7659):539–543
Chalmers SA, Wen J, Shum J, Doerner J, Herlitz L, Putterman C (2017) CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus. Clin Immunol 185:100–108
Huang MW, Stock AD, Mike EV, Herlitz L, Kolbeck R, Putterman C (2019) Anti-IFNAR treatment does not reverse neuropsychiatric disease in MRL/lpr lupus mice. Lupus 28(13):1510–1523
Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C et al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382(3):211–221
Wenzel J (2019) Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol 15(9):519–532
Vital EM, Wittmann M, Edward S, Md Yusof MY, MacIver H, Pease CT et al (2015) Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheumatol 67(6):1586–1591
Fleischmann M, Celerier P, Bernard P, Litoux P, Dreno B (1996) Long-term interferon-alpha therapy induces autoantibodies against epidermis. Dermatology 192(1):50–55
Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL (2001) Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 159(1):237–243
Blomberg S, Eloranta ML, Cederblad B, Nordlin K, Alm GV, Ronnblom L (2001) Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 10(7):484–490
Wenzel J, Worenkamper E, Freutel S, Henze S, Haller O, Bieber T et al (2005) Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 205(4):435–442
Meller S, Winterberg F, Gilliet M, Muller A, Lauceviciute I, Rieker J et al (2005) Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 52(5):1504–1516
Guiducci C, Tripodo C, Gong M, Sangaletti S, Colombo MP, Coffman RL et al (2010) Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med 207(13):2931–2942
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Hoi, A., Vincent, F., Hibbs, M.L. (2021). Advances in Translational Science to Identify New Therapies for Systemic Lupus Erythematosus. In: Hoi, A. (eds) Pathogenesis of Systemic Lupus Erythematosus. Springer, Cham. https://doi.org/10.1007/978-3-030-85161-3_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-85161-3_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-85160-6
Online ISBN: 978-3-030-85161-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)